Duk-Woo Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Leaflet Thrombosis, Is It Clinically Relevant?
  2. Racial Disparities in TAVR: Similarities and Differences
  3. Clinical Impact of Patient-Prosthesis Mismatch After TAVR
  4. Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
  5. Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
  6. How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
  7. What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
  8. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
  9. 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
  10. My Challenging LM PCI Case of the Year
  11. East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
  12. [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI
  13. Antithrombotic and Antiplatelet Choice in Complex PCI
  14. Integrated Use of Imaging and Physiology in Left Main PCI
  15. Optimal Antithrombotics After TAVR
  16. Current Status of TAVR in Korea and US: TP-TAVR Registry
  17. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  18. Balloon-Expandable SAPIEN 3 Valve
  19. Bifurcation PCI: Data, Evidence, and Guidelines
  20. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  21. Optimal Antithrombotics After TAVR: Ongoing Trials
  22. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  23. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  24. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  25. LM Bifurcation
  26. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  27. How To Do Successful Registry Studies?
  28. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  29. Highlighting 20 years of CV Protection with Lipitor
  30. PCI in Post-TAVR Patients: Beyond the Barrier
  31. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  32. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  33. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  34. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  35. Mainstream of TAVR: Minimalist Approach
  36. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  37. Minimalist TAVR with Edwards SAPIEN 3 Valve
  38. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  39. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  40. Metallic DES Are All Equivalent!
  41. TAVR in Asia: Current Challenges and Future Direction
  42. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  43. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  44. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  45. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  46. Top 10 Tips on Bifurcation PCI
  47. Heavily Calcified Lesion: Rotational Atherectomy and Others
  48. Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
  49. TAVR - Moving to Lower Risk: STS or Age Per Se?
  50. Standard vs. Minimalist TAVR: When and How to Change?
  51. [Taped Case] TAVR with Sapien
  52. CTEPH; Diagnosis & Treatment
  53. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  54. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  55. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  56. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  57. Contemporary Bifurcation PCI; How Advance over Time?
  58. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  59. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  60. Can Different DES Make a Different Outcome?
  61. Future in Transcatheter Heart Valve Treatment
  62. SYNERGY : Latest Experience from Korea
  63. Growing Importance of Evidence in the Management of High CV Risk Patients
  64. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  65. Bifurcation PCI Summary; Technique or Concept?
  66. BRS in Left Main PCI: Clinical Data and Experience
  67. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  68. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  69. BVS: They Will Replace Metallic DES?
  70. Comparative Outcomes of New-Generation DES: IRIS-DES
  71. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  72. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  73. RDN; Indications & Evidence and Future
  74. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  75. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  76. AMC Experience of the Intervention for the Structural Heart Disease
  77. Early DES - What Did We Learn - Updates from the ZEST Trial
  78. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  79. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  80. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  81. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  82. Wrapping Up Current Clinical Trials and Future Study Program
  83. VH AMC Clinical Experience
  84. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  85. Impact of DES on Diabetes Mellitus in Long Coronary Lesion